Skip to content

Ribociclib

Ribociclib (Kisqali) is a CDK4/6 inhibitor used with hormonal treatment for hormone receptor-positive, HER2-negative breast cancer. This catalogue lists Kisqali and Ribociclib Tablets in tablet form.

Kisqali

Breast Cancer

200mg

Ribociclib tablets for breast cancer. It blocks the signals that tell cancer cells to divide, slowing their spread.

From$93.60/ tabletView

Ribociclib Tablets

Breast Cancer

200mg

Ribociclib tablets for breast cancer. It blocks enzymes that help cancer cells divide.

From$20.87/ tabletView

Key points

  • Blood counts can fall during treatment. In an early breast cancer trial, 94% of people had lower neutrophil counts, including 45% with grade 3 or 4 falls.
  • Heart rhythm may be affected because ribociclib can prolong the QT interval in a concentration-dependent way.
  • Liver function tests are carried out before treatment starts and monitored after it begins.

What Ribociclib is used for

Ribociclib succinate is used with an aromatase inhibitor for stage II or III early Breast Cancer at high risk of recurrence. For advanced or metastatic disease, Kisqali is used with an aromatase inhibitor as initial endocrine treatment, or with fulvestrant as initial treatment or after earlier endocrine treatment.

Further reading